Nabriva prices two pneumonia antibiotic versions at over $200 per day

(Reuters) - Nabriva Therapeutics Plc on Monday priced an oral and injectable version of its antibiotic Xenleta, which treats community-acquired pneumonia, at more than $200 per day after it received approval from the U.S. Food and Drug Administration.

FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is shown in Silver Spring, Maryland, November 4, 2009. REUTERS/Jason Reed/File Photo

The drug, also called lefamulin, works by interfering with the bacteria’s ability to replicate. It’s the first drug by the company to be approved by the FDA and is expected to launch in mid-September.

Shares of the company rose 23% to $2.80 after the bell.

The company said the injectable would have a list price of $205 per day, and the oral version would be $275 per day a patient receives treatment. However, the list price is not necessarily what patients actually pay as “out-of-pocket” costs vary based on the duration of the treatment and individual healthcare plans.

Although a number of patients reported side effects such as diarrhea and vomiting during the drug trial, the company said the effects were well within the range of other antibiotics taken orally.

Nabriva estimates about 5 million to 6 million Americans are diagnosed with community-acquired bacterial pneumonia every year, making it a leading cause of infectious deaths and hospitalization in the United States.

Pneumonia is generally treated with antibiotics such as moxifloxacin or levofloxacin, many of which have become ineffective as bacteria become resistant to the commonly prescribed treatments.

In April, the FDA declined to approve the company’s other antibiotic Contepo for urinary tract infections, citing manufacturing deficiencies at a contract manufacturer. Nabriva on Friday said it would re-apply for FDA approval early in the fourth quarter of 2019.

“Lefamulin is a bigger opportunity than Contepo. But we still don’t think Contepo is dead ... there’s just a little delay going on there with the FDA,” Wedbush analyst Robert Driscoll said ahead of the decision.

Driscoll expects Xenleta to initially struggle as it penetrates the market and expects the drug to bring in peak sales of $267 million by the end of 2025.

Reporting by Saumya Sibi Joseph and Arundhati Sarkar in Bengaluru; Editing by Anil D’Silva, Bernard Orr